Jeffrey G. Supko

Jeffrey G. Supko

Auto-generated profile, based on publicly available information

Jeffrey G. Supko

Massachusetts General Hospital, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
KBKristie A. Blum
Kristie A. Blum
JSJeffrey G. Supko
Jeffrey G. Supko
MMMichael B. Maris
Michael B. Maris
IFIan W. Flinn
Ian W. Flinn
AGAndre Henri Goy
Andre Henri Goy
JAJeremy S. Abramson
Jeremy S. Abramson
Purpose: NF-κB, a transcription factor essential for inflammatory responses, is constitutively activated in many lymphomas. In preclinical studies, pelabresib (CPI-0610), an investigational (BET) bromodomain inhibitor, downregulated NF-κB signaling and demonstrated antitumor activity in vitro. Here we report the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity from the first-in-human phase I study of pelabresib in patients with relapsed/refractory lymphomas (NCT01949883).Experimental Design: Sixty-four patients with relapsed/refractory lymphoma (median of 4 prior lines of therapy) were treated with either capsule (6, 12, 24, 48, 80, 120, 170, 230, 300 mg) or tablet (125, 225 mg) doses of pelabresib orally once daily on a 14 days on, 7 days off schedule.Results: The MTD was determined as the 225 mg tablet daily. The most frequent adverse events were fatigue, nausea, and decreased appetite. Thrombocytopenia, a class effect for all BET inhibitors, was dose-dependent, reversible, and noncumulative. Pelabresib exhibited dose-proportional increases in systemic exposure, rapid absorption, and a half-life of approximately 15 hours (supporting once daily dosing). The bioavailability of the tablet formulation was 60% greater than the capsules. Pelabresib suppressed IL8 and CCR1 mRNA at doses above 120 and 170 mg, respectively. Four patients (6.2%) had an objective response (2 complete response and 2 partial response) and 5 patients had prolonged stable disease.Conclusions/Discussion: Pelabresib is capable of BET target gene suppression in an exposure-dependent manner with an acceptable safety profile leading to the recommended phase II dose of the 125 mg tablet once daily.Significance: BET proteins inhibition can potentially modify the pathogenic pathways which contribute to many diseases including malignancies. Pelabresib (CPI-0610), a potent and selective small molecule BET proteins inhibitor, has a MTD of 225 mg once daily for 14 days with a 7-day break, clear pharmacokinetic/pharmacodynamic relationship, and manageable clinical safety profile. These findings are part of the foundation for the ongoing pivotal study of pelabresib in patients with myelofibrosis.

1 December 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ATAbhishek Tripathi
Abhishek Tripathi
JSJeffrey G. Supko
Jeffrey G. Supko
KGKathryn P. Gray
Kathryn P. Gray
ZMZachary J. Melnick
Zachary J. Melnick
MRMeredith M. Regan
Meredith M. Regan
LHLauren C. Harshman
Lauren C. Harshman
Purpose: Androgen receptor (AR) inhibition can upregulate c-MET expression, which may be a resistance mechanism driving progression of castration-resistant prostate cancer (CRPC). We conducted a phase I trial investigating the safety and pharmacokinetics of a potent c-MET inhibitor, crizotinib, with the AR antagonist, enzalutamide, in CRPC. Patients and Methods: Employing a 3+3 dose-escalation design, we tested three dose levels of crizotinib (250 mg daily, 200 mg twice a day, and 250 mg twice a day) with standard-dose enzalutamide (160 mg daily). The primary endpoint was rate of dose-limiting toxicities (DLTs). Tolerability and pharmacokinetics profile were secondary endpoints. Results: Twenty-four patients were enrolled in the dose-escalation (n = 16) and dose-expansion (n = 8) phases. Two DLTs occurred in dose escalation (grade 3 alanine aminotransferase elevation). The MTD of crizotinib was 250 mg twice a day. Most frequent treatment-related adverse events were fatigue (50%), transaminitis (38%), nausea (33%), and vomiting, constipation, and diarrhea (21% each). Grade ≥3 events (25%) included transaminitis (n = 2), fatigue (n = 1), hypertension (n = 1), pulmonary embolism (n = 1), and a cardiac event encompassing QTc prolongation/ventricular arrhythmia/cardiac arrest. Median progression-free survival was 5.5 months (95% confidence interval, 2.8–21.2). Pharmacokinetics analysis at the MTD (n = 12) revealed a mean Cmaxss of 104 ± 45 ng/mL and AUCτss of 1,000 ± 476 ng•h/mL, representing a 74% decrease in crizotinib systemic exposure relative to historical data (Cmaxss, 315 ng/mL and AUCτss, 3,817 ng•h/mL). Conclusions: Concurrent administration of enzalutamide and crizotinib resulted in a clinically significant 74% decrease in systemic crizotinib exposure. Further investigation of this combination in CRPC is not planned. Our results highlight the importance of evaluating pharmacokinetics interactions when evaluating novel combination strategies in CRPC.

1 December 1992 in Journal of Liquid Chromatography
Verified
Journal Article
Closed access
JSJeffrey G. Supko
Jeffrey G. Supko
LMLouis Malspeis
Louis Malspeis
Through preclinical studies by the Developmental Therapeutics Program of the National Cancer Institute with 9-amino-20(S)-camptothecin (AC), this new investigational anticancer agent will soon enter phase I clinical trials in cancer patients. During initial attempts to monitor the drug in biological fluids, it became evident that the presence of an amino group on the camptothecin A-ring suppressed the intense native fluorescence characteristic of the unsubstituted compound. However, subsequent spectro-fluorometric studies revealed that the fluorescence of AC was highly pH-dependent in a manner not typically exhibited by aromatic amines. The uncharged species that exists in neutral and weakly acidic solution is nonfiuorescent. Protonation of the C-9 amino group proceeds with the development of fluorescence, the intensity of which is optimum in moderately acidic solution of apparent pH 1.7-2.3. Under more strongly acidic conditions, fluorescent intensity again diminishes due to further protonation at the quinoline nitrogen atom. Therefore, postcolumn acidification prior to fluorescence detection provided a convenient and sensitive method to monitor the elution of AC during liquid chromatography. Following protein precipitation induced by mixing with a solution of the internal standard, camptothecin, in methanol chilled to -70 °C, plasma samples were separated on a 5 μm Ultrasphere ODS column (4.6 mm × 25 cm) using an isocratic mobiie phase composed of acetonuliie-methanoi-0.1 M ammonium acetate buffer, pH 5 5 (23: 0:67, v/v/v) at a flow rate of 1.0 ml min. Prior to detection, the column effluent was mixed inline with 0.3 M aqueous trifluoroacetic acid at a flow rate of 0.3 ml/min and ambient temperature. Fluorescence was then monitored using an excitation wavelength of 352 nm and a 418 nm emission cutoff filter. Typical retention times of the drug and internal standard were 7 and 12 min, respectively. Employing sample volumes of 50 μl, the lowest plasma concentration of AC included in the standard curve, 13.3 nM (5.0 ng/ml) was quantified with a 7.63% coefficient of variation (n = 10).

17 January 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
ELEudocia Q. Lee
Eudocia Q. Lee
BABrian M. Alexander
Brian M. Alexander
CRCarlos Guillermo Romo
Carlos Guillermo Romo
JSJeffrey G. Supko
Jeffrey G. Supko
NANathalie Y.R. Agar
Nathalie Y.R. Agar
PWPatrick Y. Wen
Patrick Y. Wen
Purpose: Adavosertib is an oral small-molecule inhibitor of Wee1. The Adult Brain Tumor Consortium conducted a phase I study evaluating adavosertib in combination with radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM), as well as a surgical window-of-opportunity study in recurrent GBM. Patients and Methods: The MTD of adavosertib was determined in adult patients with newly diagnosed GBM using a standard 3+3 design in two separate cohorts: with concurrent RT/TMZ or with adjuvant TMZ. A combination cohort with both concurrent and adjuvant adavosertib at MTD followed. We also performed intratumoral drug distribution studies in patients with recurrent GBM undergoing surgery. Results: As separate cohorts, the MTD for concurrent adavosertib with RT/TMZ was 200 mg daily Monday through Friday × 6 weeks during RT, and the MTD for adjuvant adavosertib with TMZ was 425 mg daily for 5 days of each 28-day cycle. However, six of 12 patients experienced dose-limiting toxicities (DLT) in the combination cohort. The mean ratios of the intratumoral to plasma concentration of adavosertib were 4.18 ± 3.36 for contrast-enhancing tissue and 0.74 ± 0.63 in nonenhancing tissue. Conclusions: Adavosertib at 200 mg daily Monday through Friday × 6 weeks with RT/TMZ and at 425 mg daily on a 5-day/28-day cycle with TMZ had an unacceptable DLT rate. Additional dose levels in combination cohorts resulted in DLT, and we deemed concurrent adavosertib too toxic for further examination. Adavosertib 425 mg daily on a 5-day/28-day cycle with adjuvant TMZ is the recommended phase II dosage. Tissue pharmacokinetics in tissue homogenates and by microdialysis provided complementary information about drug penetration.

20 June 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SPS. Phuphanich
S. Phuphanich
JSJ. Supko
J. Supko
KCK. A. Carson
K. A. Carson
SGS. A. Grossman
S. A. Grossman
LNLouis Nabors
Louis Nabors
JOJeffrey J. Olson
Jeffrey J. Olson
1567 Background: Bortezomib is a selective inhibitor of the proteasome that has been approved for the treatment of multiple myeloma and has also shown promising evidence of clinical activity agains...

20 June 2007 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LNLouis Nabors
Louis Nabors
MRM. Rosenfeld
M. Rosenfeld
MCM. Chamberlain
M. Chamberlain
SPS. Phuphanich
S. Phuphanich
TBT. Batchelor
T. Batchelor
SGS. Grossman
S. Grossman
2058 Background: Sorafenib (BAY 43–9006) is a small molecule inhibitor of multiple kinases to include raf, VEGF receptors, and PDGF receptors. The molecule has demonstrated anti-proliferative and anti-angiogenic activity in a number of in vitro and in vivo model systems. Methods: In this multi-institutional trial, we have conducted a phase I dose-escalation study to determine the maximum tolerated dose (MTD) of sorafenib in patients with recurrent malignant glioma. Cohorts of 3 patients, stratified based on the use of enzyme inducing anticonvulsants (EIAC) or not (non-EIAC), have completed enrollment through the following dose levels: 200 mg, 400 mg, 600 mg, and 800 mg. Therapy has been given as a twice daily oral administration with cycles of 28 day duration. Results: A total of 35 patients have been enrolled and are evaluable for toxicity. Treatment related dose-limiting toxicity (DLT) was defined as any grade 3 or 4 non-hematological toxicity, and grade 4 hematological toxicity (platlets and ANC) or febrile neutropenia of any duration. The following DLTs were observed: one grade 3 hand-foot-syndrome at the 400 mg BID (EIAC), one grade 3 puritis 400 mg BID (non-EIAC) dose level, grade 3 hand/foot syndrome 800 mg BID (EIAC and non-EIAC arms), grade 3 hypophosphatemia 800 mg BID (EIAC), and grade 3 joint pain 800 mg BID (EIAC). A MTD of 600 mg BID has been defined for the EIAC arm with 3/6 DLTs at 800 mg BID. A MTD has not been defined and enrollment has been completed through the 800 mg BID dose level for the non-EIAC. Of the enrolled patients, 20 are with glioblastoma multiforme (GBM), 8 with anaplastic astrocytoma (AA), and 7 with anaplastic oligodendroglioma (AO). Conclusions: The MTD for sorafenib is 600 mg BID for patients on EIAC. Sorafenib is well tolerated with limited toxicities to doses of 800 mg twice daily in patients with recurrent malignant glioma not on EIAC (non-EIAC arm). No significant financial relationships to disclose.